Medegen extends distribution horizons with Bard deal
This article was originally published in Clinica
Executive Summary
Infusion therapy specialist Medegen will make its MaxPlus Clear needle-less access connector available with CR Bard’s inserted central catheter (PICC) kits, after the two firms came together in a co-marketing deal. The agreement, of which full financial details were not disclosed, will see the MaxPlus Clear included in products such as the Bard PowerPICC Solo, thus extending Medegen’s distribution reach. The MaxPlus Clear is manufactured by Medegen’s Maximus subsidiary and is claimed to be “the first and only positive displacement connector that features complete visualisation of the fluid path, which is shown to enhance patient care, leading to lower bloodstream infection and occlusion rates,” according to Ontario, California-based Medegen.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals